Welcome to our dedicated page for Medicure news (Ticker: MCUJF), a resource for investors and traders seeking the latest updates and insights on Medicure stock.
Medicure (MCUJF) delivers innovative therapeutic solutions through pharmaceutical development and direct-to-consumer pharmacy services. This page provides authorized updates on the company's clinical advancements, regulatory milestones, and strategic business decisions.
Access real-time press releases covering earnings reports, drug development progress (including MC-1 clinical trials), and operational expansions like the Gateway Medical Pharmacy acquisition. Investors will find essential updates on Marley Drug's nationwide distribution network and regulatory designations such as Orphan Drug statuses.
Our curated news feed serves as a comprehensive resource for tracking Medicure's dual focus on cardiovascular treatments and neurometabolic disorder solutions. Stay informed about product commercialization efforts, intellectual property developments, and compliance achievements that shape the company's market position.
Bookmark this page for verified updates on Medicure's pharmaceutical innovations and pharmacy service enhancements. Check regularly for new developments in therapeutic research and healthcare distribution strategies.
Medicure Inc. (TSXV:MPH)(OTC:MCUJF) has announced the signing of a definitive agreement to acquire Gateway Medical Pharmacy Inc. through its U.S. subsidiary, Medicure Pharma Inc. The agreement, signed on February 14, 2025, represents a strategic expansion of Medicure's direct-to-consumer pharmacy business.
Gateway generated unaudited revenue of approximately $3.1 million and net income of $271,000 for the 12-month period ended December 31, 2024. The acquisition aims to enhance Medicure's ZYPITAMAG® distribution, improve patient access, increase medication adherence, and reduce distribution costs.
The transaction requires no financing or debt acquisition by Medicure, and no finder fees will be paid. The closing is subject to various conditions, including the transfer of agreements and licenses to Medicure.
Medicure reported Q3 2024 financial results with total net revenue of $5.2 million, up from $5.0 million in Q3 2023. AGGRASTAT sales decreased to $1.9 million from $2.4 million, while Marley Drug business revenue increased to $2.7 million from $2.2 million. Net income rose to $680,000 ($0.07 per share) from $84,000 ($0.01 per share) year-over-year. However, adjusted EBITDA turned negative at -$467,000 compared to positive $429,000 in Q3 2023. Cash position decreased to $4.9 million from $6.4 million at year-end 2023.
Medicure (TSXV:MPH)(OTC PINK:MCUJF) has scheduled its Q3 2024 financial results presentation for November 26, 2024, at 8:30 AM ET. The Q3 financials will be filed after market close on November 25, 2024. The company also announced the resignation of Board member Kimberly Kramchynsky, effective November 18, 2024, citing personal reasons. The conference call will be accessible via toll-free and international numbers, with a webcast option available. A Q&A session will follow the presentation, and a recording will be available on the company's website afterward.
Medicure has announced a successful settlement of product development and supply contracts between its subsidiaries Medicure International Inc. & Medicure Pharma Inc. and an undisclosed third party. The company has received a €1.5 million settlement payment as part of the final agreement. The remaining terms of the settlement and the identity of the third party remain confidential.
Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF) reported financial results for Q2 2024. Total net revenue decreased to $5.2 million from $6.0 million in Q2 2023. AGGRASTAT sales declined to $1.8 million from $2.6 million. Marley Drug business revenue remained stable at $2.7 million. ZYPITAMAG sales increased slightly to $1.4 million from $1.3 million. The company reported a net loss of $1.2 million ($0.12 per share) compared to a net income of $253,000 ($0.03 per share) in Q2 2023. Adjusted EBITDA was negative $514,000, down from $948,000. Cash and cash equivalents stood at $5.9 million as of June 30, 2024.
Medicure, a pharmaceutical company, announced an asset purchase agreement with CanAm Bioresearch to acquire patents and intellectual property related to new chemical entities for therapeutic use. Medicure will pay CanAm $100,000 upfront and up to $1.25 million in milestone payments, plus 10% of net proceeds from asset-related transactions, capped at $20 million. The deal includes the option for CanAm to repurchase the assets if Medicure fails to file an IND application within seven years. The agreement remains subject to regulatory approvals and customary closing conditions.
Medicure (TSXV:MPH) (OTC PINK:MCUJF) reported financial results for Q1 2024, ending March 31, 2024. The company recorded net revenue of $5.7 million, a slight increase from $5.6 million in Q1 2023. AGGRASTAT revenue fell to $2.3 million from $2.7 million, while Marley Drug revenue rose to $2.7 million from $2.3 million. Adjusted EBITDA decreased to $359,000 from $916,000, and net income dropped to $51,000 from $290,000. The decrease was attributed to higher expenses and lower AGGRASTAT sales. The company had $6.1 million in unrestricted cash as of March 31, 2024.
Additionally, all six nominees, including new director Kimberly Kramchynsky, were elected at the annual general meeting. The company will host a conference call on May 29, 2024, to discuss the results.
FAQ
What is the current stock price of Medicure (MCUJF)?
What is the market cap of Medicure (MCUJF)?
